Niagen Bioscience, Inc.
NASDAQ: NAGE · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Niagen Bioscience, Inc. (NAGE) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $580.00 | $4.08M | $3.57M | $6.51M | $6.27M | $9.03M | $8.99M | $11.52M | $18.75M | $19.75M | $62.72M | $42.23M | $40.25M | $38.36M | $57.84M | $54.06M | $54.96M | $68.28M | $106.41M |
| Cash & equivalents | $580.00 | $1.13M | $471378.00 | $2.23M | $420152.00 | $520000.00 | $2.26M | $3.96M | $5.55M | $1.64M | $45.39M | $22.42M | $18.61M | $16.50M | $28.02M | $20.29M | $27.17M | $44.51M | $64.79M |
| Current assets | $580.00 | $2.30M | $2.01M | $4.90M | $4.95M | $7.93M | $5.79M | $9.90M | $16.55M | $15.74M | $57.18M | $36.53M | $33.52M | $32.22M | $48.91M | $46.57M | $49.53M | $64.10M | $96.81M |
| Total liabilities | $400.00 | $2.33M | $2.52M | $1.57M | $3.71M | $5.04M | $3.32M | $7.52M | $13.47M | $9.78M | $8.89M | $15.05M | $19.80M | $21.93M | $26.11M | $25.39M | $26.51M | $22.18M | $29.87M |
| Current liabilities | $400.00 | $2.07M | $2.19M | $1.14M | $3.34M | $4.76M | $2.84M | $4.98M | $9.59M | $8.87M | $8.09M | $14.44M | $15.06M | $16.48M | $17.61M | $17.87M | $20.62M | $17.95M | $19.92M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Shareholder equity | $180.00 | $1.75M | $1.05M | $4.94M | $2.56M | $3.99M | $5.67M | $4.00M | $5.27M | $9.97M | $53.83M | $27.18M | $20.45M | $16.42M | $31.73M | $28.67M | $28.46M | $46.09M | $76.53M |
| Retained earnings | $-39820.00 | $-7.20M | $-8.11M | $-10.16M | $-18.05M | $-29.72M | $-34.14M | $-39.52M | $-42.30M | $-45.22M | $-56.60M | $-89.75M | $-121.90M | $-141.82M | $-168.95M | $-185.49M | $-190.46M | $-181.91M | $-164.53M |
| Accounts receivable | — | $349052.00 | $497928.00 | $1.00M | $723666.00 | $1.94M | $1.05M | $1.91M | $2.45M | $5.85M | $5.34M | $4.42M | $2.17M | $2.69M | $5.23M | $8.48M | $5.23M | $7.77M | $9.74M |
| Inventory | — | $711584.00 | $922760.00 | $1.42M | $2.91M | $5.21M | $2.20M | $3.73M | $8.17M | $7.91M | $5.80M | $8.25M | $11.54M | $11.68M | $13.60M | $14.68M | $14.53M | $9.19M | $20.42M |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Frequently asked questions
What is Niagen Bioscience, Inc.'s revenue?
Niagen Bioscience, Inc.'s trailing twelve-month revenue is $130.42M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is NAGE?
In its most recent fiscal year, NAGE ran a gross margin of 64.28%, an operating margin of 11.05%, and a net margin of 13.43%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does NAGE generate?
NAGE produced $13.14M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is NAGE's balance sheet healthy?
NAGE holds $64.79M in cash and equivalents against — in long-term debt, on $76.53M of shareholder equity. That debt is best read against the cash flow the business throws off each year.